INSTITUT GUSTAVE ROUSSY - France 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2019
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:500-600
Total Number of Projects:> 1000
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):900-1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:300-400
Total Number of Projects:65
Total Project Funding:400-500
Networking Rank (Reputation):500-600
Networking Rank (Reputation):500-600
Partner Constancy:46
Project Leadership Index:75
Diversity Index:18
2011
Criterium:Position:
Overall Score:800-900
Total Project Funding per Partner:200-300
Total Number of Projects:200-300
Total Project Funding:100-200
Networking Rank (Reputation):200-300
Partner Constancy:100-200
Project Leadership Index:600-700
Diversity Index:> 1000
2009
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:700-800
Total Number of Projects:> 1000
Total Project Funding:600-700
Networking Rank (Reputation):> 1000
Partner Constancy:600-700
Project Leadership Index:500-600
Diversity Index:> 1000
2008
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:600-700
Project Leadership Index:500-600
Diversity Index:500-600
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:300-400
Total Number of Projects:600-700
Total Project Funding:400-500
Networking Rank (Reputation):> 1000
Partner Constancy:400-500
Project Leadership Index:400-500
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2022-12-31 ):

Total Project Funding:

Funding per Partner:

Projects:

Leadership:

Total number of projects: 35
As coordinator: 2
As participant: 31
Sole participant: 2
Coordinator / Participant Ratio: 0.06*

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 8.897.709 140.942 3
2020 0 28.999.948 851.989 3
2019 14.994.551 6.999.989 2.644.625 1 1
2018 0 12.436.859 540.750 1
2017 0 16.523.625 1.086.240 3
2016 1.500.000 0 1.500.000 1
2015 0 7.476.725 262.876 2
2013 2.998.355 11.662.081 1.517.283 1 2
2012 268.555 25.088.618 2.270.829 1 5
2011 0 63.192.794 4.425.298 11

Networking:

Partners:

Institution:Projects [No]:
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM9
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE8
KAROLINSKA INSTITUTE7
UNIVERSITY OF BIRMINGHAM7
CHARITE UNIVERSITAETSMEDIZIN BERLIN5
INSTITUT CURIE5
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS5
UNIVERSITY COLLEGE LONDON5
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM4
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL4
ST ANNA KINDERKREBSFORSCHUNG4
UNIVERSITA DEGLI STUDI DI TORINO4
UNIVERSITY OF CAMBRIDGE4
ACADEMISCH ZIEKENHUIS LEIDEN3
COMMISSARIAT A L'ENERGIE ATOMIQUE3
DEUTSCHES KREBSFORSCHUNGSZENTRUM3
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI3
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON3
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III3
GSF FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT3
INSTITUT JULES BORDET3
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER3
ISTITUTO GIANNINA GASLINI3
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI3
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN3
PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV3
SIOP EUROPE3
STICHTING KATHOLIEKE UNIVERSITEIT3
THE UNIVERSITY OF MANCHESTER3
UNIVERSITAET ZUERICH3
UNIVERSITAETSKLINIKUM ESSEN3
UNIVERSITY OF NEWCASTLE UPON TYNE3
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
BELGIAN NUCLEAR RESEARCH CENTRE2
CENTRE ANTICANCEREUX LEON BERARD2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
CONSIGLIO NAZIONALE DELLE RICERCHE2
DANISH CANCER SOCIETY2
DEPARTMENT OF HEALTH2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
ENTE PER LE NUOVE TECNOLOGIE L'ENERGIA E L'AMBIENTE2
EUROPEAN CANCER ORGANISATION2
EUROPEAN MOLECULAR BIOLOGY LABORATORY2
F HOFFMANNLA ROCHE2
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O2
GBG FORSCHUNGS2
GESELLSCHAFT FUER SCHWERIONENFORSCHUNG MBH2
INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER ASSOCIATION2
INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE2
INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL2
ISTITUTO EUROPEO DI ONCOLOGIA2
ISTITUTO ORTOPEDICO RIZZOLI2
LEIDEN UNIVERSITY MEDICAL CENTER2
MASARYKOVA UNIVERZITA2
MEDIZINISCHE UNIVERSITAET WIEN2
OSLO UNIVERSITETSSYKEHUS HF2
PHILIPPS UNIVERSITAET MARBURG2
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON2
REGION HOVEDSTADEN2
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU2
SARCOMA PATIENTS EURONET EV2
SEMMELWEIS EGYETEM2
STATE INSTITUTION RESEARCH CENTER FOR RADIATION MEDICINE OF THE ACADEMY OF MEDICAL SCIENCES OF UKRAINE2
STICHTING ANTONI VAN LEEUWENHOEK ZIEKENHUIS2
STOCKHOLM UNIVERSITET2
STUDIECENTRUM VOOR KERNENERGIE2
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE2
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD2
THE CHRISTIE NHS FOUNDATION TRUST2
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA2
THE ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST2
THE UNIVERSITY OF NOTTINGHAM2
UNICANCER2
UNIVERSITA DEGLI STUDI DI MILANO BICOCCA2
UNIVERSITA DEGLI STUDI DI PADOVA2
UNIVERSITA DEGLI STUDI DI TRENTO2
UNIVERSITAET BERN2
UNIVERSITATSKLINIKUM ERLANGEN2
UNIVERSITE PARIS CITE2
UNIVERSITY OF AARHUS2
UNIVERSITY OF LEEDS2
UPPSALA UNIVERSITET2
WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTER2
AARHUS KOMMUNEHOSPITAL AARHUS UNIVERSITY HOSPITAL1
ACADEMISCH ZIEKENHUIS GRONINGEN1
ACZON1
ADIMEC ADVANCED IMAGE SYSTEMS BV1
AGENCE NATIONALE DE SANTE PUBLIQUE1
AGES OSTERREICHISCHE AGENTUR FUR GESUNDHEIT UND ERNAHRUNGSSICHERHEIT1
AIT AUSTRIAN INSTITUTE OF TECHNOLOGY1
ALGOE1
ALLEANZA CONTRO IL CANCRO1
ALMA CONSULTING GROUP SAS1
AMSTERDAM BIOTHERAPEUTICS UNIT1
AQUAMARIJN MICRO FILTRATION BV1
ARIANA PHARMACEUTICALS1
ARISTOTLE UNIVERSITY OF THESSALONIKI1
ASPER BIOTECH1
ASSOCIACAO DO INSTITUTO SUPERIOR TECNICO PARA A INVESTIGACAO E DESENVOLVIMENTO1
ASSOCIATION EUROPEENNE DES LIGUES CONTRE LE CANCER ASBL1

Constancy:

Total number of partners: 503
Partner loyalty:
Frequent Partner: (> 2 projects): 128
Rare Partner: 375
Frequent / Rare Partner Ratio: 0.34

Project overview:

Start dateProjectacronymrolefundingpartners
2021-05-01International Human Microbiome Coordination and Support Action IHMCSAparticipant1.999.37017
2021-02-01Building Data Rich Clinical Trials CCE_DARTparticipant5.999.41112
2021-01-01Twinning in Research and Education to improve survival in Childhood Solid Tumours in Lithuania TRELparticipant898.92810
2020-09-01Towards effective radiation protection based on improved scientific evidence and social considerations - focus on radon and NORM RadoNormparticipant18.000.00060
2020-01-014-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening 4-IN THE LUNG RUNparticipant7.999.94910
2020-01-01Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation. NeutroCureparticipant2.999.99910
2019-06-01Health effects of cArdiac fluoRoscopy and MOderN radIotherapy in paediatriCs HARMONICparticipant6.999.98924
2019-01-01Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. ONCOBIOMEcoordinator14.994.55118
2018-01-01International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70 MyPeBSparticipant12.436.85929
2017-12-01A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma. CLINGLIOparticipant6.155.12512
2017-11-01Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research SilkFUSIONparticipant2.998.5006
2017-01-01ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 ITCC-P4participant7.370.00021
2016-12-01Resistance mechanisms to tyrosine kinase inhibitors in solid tumors TKI resistancecoordinator1.500.0001
2015-12-01Training Network for the Immunotherapy of Cancer IMMUTRAINparticipant3.627.52510
2015-09-01ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer ALKATRASparticipant3.849.20023
2013-10-01EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma EECparticipant5.697.83120
2013-06-01Mutanome Engineered RNA Immuno-Therapy MERITparticipant5.964.2505
2013-03-01WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients WINTHERcoordinator2.998.35511
2012-11-01Non-Invasive Optical Biopsy for Cancer Assessment using ultra high resolution Full-Field Optical Coherence Tomography CAReIOCAparticipant3.099.4815
2012-10-01Rational molecular Assessments and Innovative Drug Selection RAIDSparticipant5.999.64216
2012-09-01Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients CTCTRAPparticipant6.000.00012
2012-08-01Genetic epidemiological investigation into the association between endometriosis and cutaneous melanoma MELENDO2coordinator268.5551
2012-04-01Biomaterials for Tracheal Replacement in Age-related Cancer via a Humanly Engineered Airway BIOtracheaparticipant3.999.30013
2012-02-01Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer RESPONSIFYparticipant5.990.19512
2011-12-01STRENGTHENING COOPERATION IN MOLECULAR BIOMEDICINE BETWEEN EU AND UKRAINE COMBIOMparticipant455.4993
2011-12-01European Clinical trials in Rare Sarcomas within an integrated translational trial network EUROSARCparticipant5.953.83218
2011-10-01Cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation PROCARDIOparticipant2.998.38713
2011-10-01Cognitive and Cerebrovascular Effects Induced by Low Dose Ionising Radiation CEREBRADparticipant2.999.51712
2011-04-01Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE ARTFORCEparticipant5.994.71514
2011-02-01PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies PanCareSurFupparticipant5.993.69517
2011-01-01EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS ENCCAparticipant11.997.95934
2011-01-01Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics PREDICTparticipant5.841.00914
2011-01-01A European Platform for Translational Cancer Research EUROCANPLATFORMparticipant11.998.45428
2011-01-01Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis CURELUNGparticipant2.965.74911
2011-01-01European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults ENS@T-CANCERparticipant5.993.97816

Alias institution names:

  • INSTITUT GUSTAVE ROUSSY